“Anti-inflammatory” is a broad description, not a complete treatment claim. Inflammation can be protective, harmful or both depending on the setting. An experiment showing a change in one pathway does not establish that a compound improves every inflammatory condition.

KPV research provides an example. A primary study investigated peptide transport and inflammatory signaling in cell systems and mouse colitis models. Those findings are preclinical, even where human-derived cell lines were used. They do not constitute a clinical trial in people with inflammatory bowel disease. PepT1 mediated KPV uptake and inflammation in cells and mice

Name the level of evidence

Cell experiments can explore a mechanism. Animal models can test how an intervention behaves in a more complex system. Human trials must then determine whether a relevant patient outcome improves with acceptable risk. The steps are connected, but they are not interchangeable.

A useful endpoint could be a validated disease measure, symptoms, function or a clinical event. A cytokine change can support biological interpretation while still leaving the patient benefit unresolved. The direction of a laboratory marker should not be assumed to be beneficial in every context.

Policy and efficacy are separate questions

The 2026 HHS peptide-compounding policy describes a conditional enforcement approach. It does not add clinical outcome evidence or turn a mechanistic result into proof of effectiveness. HHS interim peptide compounding enforcement discretion policy

AXON therefore avoids ranking peptides as universal inflammation treatments. A responsible review names the molecule, disease, study model, comparator and outcome. It then explains how far the evidence can be taken and what would be required to support a stronger claim.

For someone with persistent inflammatory symptoms or a diagnosed condition, evidence-based clinical assessment is more useful than choosing an experimental compound from a general list. This article offers a framework for reading the research, not a substitute for disease-specific care.